Drugs / RC010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07528703 | Apr 2026 → Apr 2027 expected | idiopathic pulmonary fibrosis | Nanjing Reju Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07528703 ↗ |
| Modality | Small molecule | “RC010 is a small-molecule drug” NCT07528703 ↗ |
| Route | Inhaled | “RC010 Inhalation Powder” NCT07528703 ↗ |